COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Phase 1 Study of SPT-2101 Given as a Single Intratympanic Injection in Subjects with Unilateral Meniere's Disease
Scientific title
A Prospective, Open-Label, Single center, Phase 1 Study of SPT-2101 Given as a Single Intratympanic Injection in Subjects with Unilateral Meniere's Disease (SPT-2101 Safety in Meniere’s Disease Study)
Secondary ID [1] 304238 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Unilateral Meniere's Disease 321940 0
Condition category
Condition code
Ear 319671 319671 0 0
Other ear disorders

Study type
Description of intervention(s) / exposure
SPT-2101 is an investigational drug designed for intratympanic (IT) administration. It is composed of a chemically crosslinked hydrogel containing a suspension of dexamethasone.
Topical anesthetic will be applied to the subject’s ear drum and/or ear canal approximately 30 minutes prior to planned study drug administration, or until therapeutic effect is achieved. SPT-2101 will be delivered to the middle ear via IT administration by an ENT otolaryngologist under direct visualization.
The dose level planned is 3 mg of dexamethasone to be administered in a volume of 50 microliter of SPT-2101 containing 6% dexamethasone as a single dose with 12 weeks of post-administration follow-up.
The study drug will be prepared on site by study personal as per the Instructions for Use.
Intervention code [1] 320570 0
Treatment: Drugs
Comparator / control treatment
No control group
Control group

Primary outcome [1] 327544 0
To evaluate the safety and tolerability of a single intratympanic (IT) injection of SPT-2101 through targeted physical examination of Head, Eyes, Ears, Nose, and Throat (HEENT) in subjects with unilateral Meniere’s Disease
Timepoint [1] 327544 0
Screening period that is targeted at 4 weeks prior to Day 1; Day 1, Day 2, Day 8, Day 15, Day 29, Day 57, Day 85 post-intervention administration
Secondary outcome [1] 395619 0
To assess the pharmacokinetics of SPT-2101 in subjects with unilateral Meniere’s Disease.
Plasma samples will be collected at various times post-treatment for pharmacokinetics assessment.
The following parameter is used for evaluation during PK assessments: maximum concentration (Tmax) and area under the curve (AUC)
Timepoint [1] 395619 0
Day 0, Day 2, Day 8, Day 15, Day 29, Day 57 and Day 85 post intervention administration

Key inclusion criteria
1. Age 18 years to 70 years (inclusive) at the time of screening
2. Provides written informed consent prior to participation in any study procedure
3. Has a diagnosis of unilateral Definite Meniere's disease defined by the Classification Committee of the Bárány Society or the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS)
4. Reports two or more episodes of definitive vertigo (lasting 20 minutes or more) in the month prior to screening
5. Has documented acquired asymmetric sensorineural hearing loss, as reported by the patient or documented by audiometric testing
Minimum age
18 Years
Maximum age
70 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Ongoing chronic inflammatory or infectious middle ear disease
2. Active infection in the ear, sinuses, or upper respiratory system
3. Current tympanic membrane perforation
4. Active benign paroxysmal positional vertigo (BPPV) symptoms
5. History of superior canal dehiscence

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 19466 0
Linear Clinical Research - Nedlands
Recruitment postcode(s) [1] 34058 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 308615 0
Commercial sector/Industry
Name [1] 308615 0
Spiral Therapeutics, Inc.
Address [1] 308615 0
1000 Marina Blvd., Suite 105 Brisbane, CA 94005
Country [1] 308615 0
United States of America
Primary sponsor type
Commercial sector/Industry
Spiral Therapeutics Australia Pty Ltd
58 Gipps Street, Collingwood, 3066 Vic, Australia
Secondary sponsor category [1] 309484 0
Name [1] 309484 0
Address [1] 309484 0
Country [1] 309484 0
Other collaborator category [1] 281785 0
Commercial sector/Industry
Name [1] 281785 0
Novotech (Australia) Pty Limited
Address [1] 281785 0
Level 3, 235 Pyrmont Street, Pyrmont, NSW 2009
Country [1] 281785 0

Ethics approval
Ethics application status
Ethics committee name [1] 308547 0
Bellberry Human Research Ethics Committee
Ethics committee address [1] 308547 0
123 Glen Osmond Road, Eastwood, South Australia, 5063
Ethics committee country [1] 308547 0
Date submitted for ethics approval [1] 308547 0
Approval date [1] 308547 0
Ethics approval number [1] 308547 0

Brief summary
This is an open-label, single arm, single-dose study to evaluate the safety, tolerability, and pharmacokinetics profile of SPT-2101 following a single IT administration. In all study subjects, SPT-2101 will be delivered unilaterally (one ear will remain untreated).
Subjects will undergo a single dose of study drug administration with subsequent follow up visits over the course of 12 weeks. Each subject’s participation will last up to approximately 16 weeks.

Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 111090 0
Dr Jafri Kuthubutheen
Address 111090 0
Linear Clinical Research, Level 1, B Block, Hospital Ave, Nedlands, Western Australia, 6009
Country 111090 0
Phone 111090 0
+61 089367 8377
Fax 111090 0
Email 111090 0
Contact person for public queries
Name 111091 0
Dr Jafri Kuthubutheen
Address 111091 0
Linear Clinical Research, Level 1, B Block, Hospital Ave, Nedlands, Western Australia, 6009
Country 111091 0
Phone 111091 0
+61 089367 8377
Fax 111091 0
Email 111091 0
Contact person for scientific queries
Name 111092 0
Dr Charles Limb
Address 111092 0
Spiral Therapeutics, Inc. 1000 Marina Blvd., Suite 105 Brisbane, CA 94005, USA
Country 111092 0
United States of America
Phone 111092 0
Fax 111092 0
Email 111092 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
What supporting documents are/will be available?
No other documents available
Summary results
No Results